{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:43:42Z","timestamp":1756993422417},"reference-count":47,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,6,1]]},"DOI":"10.2169\/internalmedicine.8180-21","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T22:16:14Z","timestamp":1654035374000},"page":"1663-1671","source":"Crossref","is-referenced-by-count":6,"title":["Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study"],"prefix":"10.2169","volume":"61","author":[{"given":"Shoko","family":"Isoyama","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Japan"},{"name":"Department of Molecular and Internal Medicine, Graduate School of Biochemical and Health Sciences, Hiroshima University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhisa","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Hamai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirai","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Japan"},{"name":"Department of Molecular and Internal Medicine, Graduate School of Biochemical and Health Sciences, Hiroshima University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hiroshima Prefectural Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Tanimoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hiroshima Prefectural Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hiroshima Prefectural Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Hattori","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hiroshima Prefectural Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Global Initiative for Asthma. Global Strategy for Asthma Management and Preventions, 2019. [Internet]. [cited 2021 May 11]. Available from: http:\/\/www.ginasthma.org"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Chung KF, Wenzel SE, Brozek JL, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43: 343-373, 2014.","DOI":"10.1183\/09031936.00202013"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Fehrenbach H, Wagner C, Wegann M. Airway remodeling in asthma: what really matters. Cell Tissue Res 367: 551-659, 2017.","DOI":"10.1007\/s00441-016-2566-8"},{"key":"4","unstructured":"4. Lieberman P. Allergic remodeling. [Internet]. [cited 2021 May 31]. Available from: http:\/\/www.worldallergy.org\/education-and-programs\/education\/allergic-disease-resource-center\/professionals\/allergic-remodeling"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Inoue H, Kozawa M, Milligan KL, Funakubo M, Igarashi A, Loefroth E. A retrospective cohort study evaluating healthcare resource utilization in patients with asthma in Japan. NPJ Prim Care Respir Med 29: 13, 2019.","DOI":"10.1038\/s41533-019-0128-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Amelink M, de Groot JC, de Nijs SB, et al. Severe adult-onset asthma: a distinct phenotype. J Allergy Clin Immunol 132: 336-341, 2013.","DOI":"10.1016\/j.jaci.2013.04.052"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allery Clin Immunol 135: 299-310, 2015.","DOI":"10.1016\/j.jaci.2014.12.1871"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Halder P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 164: 749-753, 2001.","DOI":"10.1164\/ajrccm.164.5.2009035"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet 376: 803-813, 2010.","DOI":"10.1016\/S0140-6736(10)61087-2"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Bellia V, Pedone C, Catalano F, et al. Asthma in the elderly: mortality rate and associated risk factors for mortality. Chest 132: 1175-1182, 2007.","DOI":"10.1378\/chest.06-2824"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Diaz-Guzman E, Mannino DM. Airway obstructive disease in older adults: from detection to treatment. J Allergy Clin Immunol 126: 702-709, 2010.","DOI":"10.1016\/j.jaci.2010.08.022"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Abramson MJ, Perret JL, Dharmage SC, McDonald V, McDonald CF. Distinguishing adult-onset asthma from COPD: a review and a new approach. Int J Chron Obstruct Pulmon Dis 9: 945-962, 2014.","DOI":"10.2147\/COPD.S46761"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. de Groot JC, Brinke AT, Bel EHD. Management of the patients with eosinophilic asthma: a new era begins. ERJ Open Res 1: 00024-2015, 2015.","DOI":"10.1183\/23120541.00024-2015"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360: 1715-1721, 2002.","DOI":"10.1016\/S0140-6736(02)11679-5"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ilmerinen P, Tuomisto LE, Niemel\u00e4 O, Kankaanranta H. Prevalence of patients eligible for anti-IL-5 treatment in a cohort of adult-onset asthma. J Allergy Clin Immunol Pract 7: 165-174, 2019.","DOI":"10.1016\/j.jaip.2018.05.032"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ilmarinen P, Kankaanranta H. Eosinophil apoptosis as a therapeutic target in allergic asthma. Basic Clin Pharmacol Toxicol 114: 109-117, 2013.","DOI":"10.1111\/bcpt.12163"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kankaanranta H, Moilanen E, Zhang X. Pharmacological regulation of human eosinophil apoptosis. Curr Drug Targets Inflamm Allergy 4: 433-445, 2005.","DOI":"10.2174\/1568010054526395"},{"key":"18","unstructured":"18. Fala L. Nucala (Mepolizumab): first IL-5 antagonist monoclonal antibody FDA approved for maintenance treatment of patients with severe asthma. Am Health Drug Benefits 9: 106-110, 2016."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Fainardi V, Pisi G, Chetta A. Mepolizumab in the treatment of severe eosinophilic asthma. Immunotherapy 8: 27-34, 2016.","DOI":"10.2217\/imt.15.102"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Chipps BE, Hirsch I, Trudo F, Alacqua M, Zangrilli JG. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma. Ann Allergy Asthma Immunol 124: 79-86, 2020.","DOI":"10.1016\/j.anai.2019.10.006"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371: 1189-1197, 2014.","DOI":"10.1056\/NEJMoa1403291"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380: 651-659, 2012.","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371: 1198-1207, 2014.","DOI":"10.1056\/NEJMoa1403290"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 5: 390-400, 2017.","DOI":"10.1016\/S2213-2600(17)30125-X"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Bleecker ER, FitzGerald JM, Chanez P, et al.; the SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage corticosteroids and long-acting \u03b2<sub>2<\/sub>-agonists (SIROCCO): a randomised, multicenter, placebo-controlled phase 3 trial. Lancet 388: 2115-2127, 2016.","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. FitzGerald JM, Bleecker ER, Nair P, et al.; the CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, couple-blind, placebo-controlled phase 3 trial. Lancet 388: 2128-2141, 2016.","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Eng J Med 376: 2448-2458, 2017.","DOI":"10.1056\/NEJMoa1703501"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Drick N, Milger K, Seeliger B, et al. Switch from IL-5 to IL-5-receptor \u03b1 antibody treatment in severe eosinophilic asthma. J Asthma Allergy 13: 605-614, 2020.","DOI":"10.2147\/JAA.S270298"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Isoyama S, Ishikawa N, Hamai K, et al. Efficacy of mepolizumab in elderly patients with severe asthma and overlapping COPD in real-world setting: a retrospective observational study. Respir Investig 59: 478-486, 2021.","DOI":"10.1016\/j.resinv.2021.02.009"},{"key":"30","unstructured":"30. Ministry of Health, Labour and Welfare. Ethical guidelines for medical and health research involving human subjects, 2018. [Internet]. [cited 2021 May 15]. Available from: http:\/\/www.lifescience.mext.go.jp\/files\/pdf\/n2181.01.pdf"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Lugogo N, Domingo C, Chanez P, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther 38: 2058-2070, 2016.","DOI":"10.1016\/j.clinthera.2016.07.010"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Kavanagh JE, d&apos;Ancona G, Elstad M, et al. Real-world effectiveness and the characteristics of a &quot;Super-Responder&quot; to mepolizumab in severe eosinophilic asthma. Chest 158: 491-500, 2020.","DOI":"10.1016\/j.chest.2020.03.042"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Kavanagh JE, Hearn AP, Dhariwal J, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest 159: 496-506, 2021.","DOI":"10.1016\/j.chest.2020.08.2083"},{"key":"34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000324539","volume":"82","author":"N Ishikawa","year":"2011","unstructured":"34. Ishikawa N, Hattori N, Tanaka S, et al. Levels of surfactant proteins A and D and KL-6 are elevated in the induced sputum of chronic obstructive pulmonary disease patients: a sequential sputum analysis. Respiration 82: 10-18, 2011.","journal-title":"Respiration","ISSN":"http:\/\/id.crossref.org\/issn\/0025-7931","issn-type":"print"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Graham BL, Steenburggen I, Miller MR, et al. Standardization of spirometry, 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med 200: e70-e88, 2019.","DOI":"10.1164\/rccm.201908-1590ST"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med 323: 1033-1039, 1990.","DOI":"10.1056\/NEJM199010113231505"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Buhl R, Humbert M, Bjermer L, et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J 49: 1700634, 2017.","DOI":"10.1183\/13993003.00634-2017"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Bakakos A, Loukides S, Bakakos P. Severe eosinophilic asthma. J Clin Med 8: 1375, 2019.","DOI":"10.3390\/jcm8091375"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 132: 1086-1096, 2013.","DOI":"10.1016\/j.jaci.2013.05.020"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 27: 483-494, 2006.","DOI":"10.1183\/09031936.06.00137704"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Bel EH, Brinke EH. New anti-eosinophil drugs for asthma and COPD: targeting the trait! Chest 152: 1276-1282, 2017.","DOI":"10.1016\/j.chest.2017.05.019"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Ducharme ME, Prince P, Hassan N, Nair P, Boulet LP. Expiratory flows and airway inflammation in elderly asthmatic patients. Respir Med 105: 1284-1289, 2011.","DOI":"10.1016\/j.rmed.2011.04.006"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Reed CE. Asthma in the elderly: diagnosis and management. J Allergy Clin Immunol 126: 681-687, 2010.","DOI":"10.1016\/j.jaci.2010.05.035"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Papathanassiou E, Loukides S, Bakakos P. Severe asthma: anti-IgE or anti-IL-5? Eur Clin Respir J 3: 31813, 2016.","DOI":"10.3402\/ecrj.v3.31813"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol 143: 1742-1751. e7, 2019.","DOI":"10.1016\/j.jaci.2018.09.033"},{"key":"46","unstructured":"46. Busse WW, Bleecker ER, FitzGerald JM, et al.; the BORA study investigators. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Repir Med 7: 46-59, 2019."},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Ortega H, Meyer E, Brusselle G, et al. Update on immunogenicity in severe asthma: experience with mepolizumab. J Allergy Clin Immunol Pract 7: 2469-2451, 2019.","DOI":"10.1016\/j.jaip.2019.03.042"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/11\/61_8180-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:14:32Z","timestamp":1715231672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/11\/61_8180-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8180-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"article-number":"8180-21"}}